Evaluating heart markers to predict atrial fibrillation in pacemaker patients
The Role of hs Troponin I and NT-proBNP in Predicting Atrial Fibrillation in Patients With Permanent Pacemakers
This study is trying to see if certain heart markers can help predict if people with pacemakers will develop atrial fibrillation in the future.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Medicine and Pharmacy at Ho Chi Minh City Academic / other |
| Locations | 1 site (Ho Chi Minh City, None Selected) |
| Trial ID | NCT06174506 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the role of high-sensitivity Troponin I and NT-proBNP in predicting new-onset atrial fibrillation in patients with permanent pacemakers. It will collect data on various risk factors, medical history, and perform specific tests before pacemaker placement. The study will follow patients over time to assess the development of atrial fibrillation using ECG and pacemaker data. The research team will cover the costs of the tests involved.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who require a permanent pacemaker and consent to participate in the study.
Not a fit: Patients with a history of atrial fibrillation or those who are severely ill may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve early detection and management of atrial fibrillation in patients with pacemakers.
How similar studies have performed: While the specific combination of hs Troponin I and NT-proBNP in this context is novel, similar studies have shown promise in using biomarkers for predicting atrial fibrillation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient is an adult (≥ 18 years old or older) * There is indication for permanent pacemaker placement and patient agreement to permanent pacemaker placement * Patient agrees to participate in the study Exclusion Criteria: * Patients had a diagnosis of atrial fibrillation in their past history or atrial fibrillation is discovered at the time of participating in the study * Severe patients, at risk of death * Pregnant * The patient is indicated for surgery * Patients with eGFR ≤ 30 mL/min/1.73m2 * The patient has a serious infection
Where this trial is running
Ho Chi Minh City, None Selected
- Cho Ray Hospital — Ho Chi Minh City, None Selected, Vietnam (Recruiting)
Study contacts
- Principal investigator: Linh HK Duong, Master — Cho Ray Hospital
- Study coordinator: Linh HK Duong, Master, MD
- Email: khanhlinh175@gmail.com
- Phone: + 84 0366698048
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.